News

François de Brantes, M.S., MBA is a senior partner at HVC Incentives Advisory Group LLC and a member of Managed Healthcare Executive editorial advisory board. He predicts "price distortions will be revealed" in 2024.

Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.

Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.

Michael Meucci is the CEO of Arcadia. He thinks that EHRs will get an AI makeover.

Maulik P. Purohit, M.D., M.P.H., is the Chief Health Information Officer at the Lehigh Valley Health Network. He believes that "AI will enhance the patient experience" in 2024.

Joerg Schwarz, M.S., is the Senior Director of Healthcare Interoperability at Infor. He believes providers will harness the power of generative AI in 2024.

Brianna Zink, M.S.N, is the Senior Director of Health Care Product Strategy at Infor. She says staff ratios will become a burden in 2024.

This year's top multimedia content includes a video interview with Jennifer Roggenbuck, MS, LGC, of Ohio State University, who addresses the patient journey of ALS.

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.

This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.

Kelsay is the President and CEO of the Business Group on Health. She predicts that in 2024, employers will "sound the drug price alarm."

Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."

This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.

Weight-loss medications were very much in the news this year, and the pages and website of Managed Healthcare Executive were no exception. Articles on off-label use of the GLP-1s such as Ozempic (semaglutide) and the FDA approval of Zepbound (tirzepatide) garnered the most page views.

Articles about Humira biosimilars, over-the-counter hearing aids and specialty drugs were among those about healthcare and drug costs that had the most pageviews on the MHE website in 2023.

News about state bans on accumulators, Pfizer’s announcements about vaccines and cardiovascular deaths increasing because of climate change were the most viewed news items on the Managed Healthcare Executive website this year.

Men with severe or moderately severe hemophilia B continue to display low bleeding rates and very little use of replacement therapies for at least three years following a single dose of the approved gene therapy hemgenix.

There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.

Acceptance is greater in oncology than in other specialties.

Research aims to find the cause of prevalence of osteoporosis in MS patients due to lack of research.

In an effort to reduce financial and other quality of life burdens for individuals living with ulcerative colitis, Hongliang Chen and his colleagues from the Department of Gastroenterology and Hepatology at four medical centers in northeast China sought to develop a routine blood-based tool for assessing the extent and severity of ulcerative colitis.

In a study recently published in the journal Fertility and Sterility, researchers from the University of Queensland in Brisbane, Australia, evaluated the fertility treatment pathways used by participants with and without PCOS to determine which pathways resulted in more live births.

This expansion follows in response to the COVID-19 pandemic and its effect on rising mental health conditions in Massachusetts alone.

In an early 2023 brief published by KFF, CMS transparency data for 2021 revealed an average denial rate of 17% for all in-network claims, with authorization denials reported as high as 24% of denial volume for some plans and medical necessity denial rates as high as 37% for others.